

United States Senate

COMMITTEE ON FINANCE

WASHINGTON, DC 20510-6200

April 21, 2010

Via Electronic Transmission

Tony Marple
Director
Maine Office of MaineCare Services
State of Maine
11 State House Station
Augusta, ME 04333

Dear Director Marple:

In the United States, the federal and state governments spend roughly \$317 billion every year on the Medicaid program. As Ranking Member of the Senate Committee on Finance, I have an obligation to ensure that taxpayer dollars are appropriately spent on federal health care programs. Like the Medicare program, Medicaid suffers from systemic weaknesses that lead to fraud, waste, and abuse across the program, resulting in higher costs and less health care to those who are in need. The overutilization of prescription drugs, whether through drug abuse or outright fraud, plays a significant role in the rising cost of our healthcare system. The purpose of this letter is to request information regarding certain outliers in Maine's Medicaid program and what steps Maine takes to monitor rates of utilization.

In recent inquiries, I have asked the U.S. Department of Health and Human Services about physicians prescribing mental health drugs at astonishingly high rates. In addition to these concerns, a recent CNN report detailed the increasing abuse of OxyContin, Roxicodone, and Xanax. Specifically, the report described the role some pain management clinics and physicians play in the black market for these drugs. I write today to better ascertain how high rates of both mental health and pain medication utilization are affecting the Medicaid program, as well as how Maine's rates compare to the national rates.

To that end, please provide charts that list of the top ten Medicaid prescribers of the following drugs for the years 2008 and 2009. For each prescriber, please provide his/her prescriber identifier, and the number of prescriptions written per drug per year, and the total amount billed to Medicaid per drug, separated for each year.

- Abilify;
- Geodon;
- Seroquel;
- Zyprexa;

- Risperdal;
- OxyContin;
- Roxicodone; and
- Xanax.

I thank you in advance for your cooperation and request that you provide the requested documents and written responses by no later than May 5, 2010. In your reply, please format information into a chart like the examples provided below. All formal correspondence should be sent electronically in PDF format to Brian_Downey@finance-rep.senate.gov or via facsimile to (202) 228-2131. Of course should you wish to discuss this matter further, please do not hesitate to contact Christopher Armstrong of my Committee staff at (202) 224-4515.

Sincerely,



Charles E. Grassley
Ranking Member

Attachment

Drug X, 2008

Prescriber Identifier	Total prescriptions	Total billed to Medicaid
123456789	25,000	250,000
234567891	24,000	240,000
345678912	23,000	230,000
456789123	22,000	220,000
567891234	21,000	210,000
678912345	20,000	200,000
789123456	19,000	190,000
891234567	18,000	180,000
912345678	17,000	170,000
012345678	16,000	160,000

Drug X, 2009

Prescriber Identifier	Total prescriptions	Total billed to Medicaid
123456789	25,000	250,000
234567891	24,000	240,000
345678912	23,000	230,000
456789123	22,000	220,000
567891234	21,000	210,000
678912345	20,000	200,000
789123456	19,000	190,000
891234567	18,000	180,000
912345678	17,000	170,000
012345678	16,000	160,000



MaineCare Services

An Office of the
Department of Health and Human Services

John E. Baldacci, Governor

Brenda M. Harvey, Commissioner

Department of Health and Human Services

MaineCare Services

11 State House Station

Augusta, Maine 04333-0011

Tel: 1-866-796-2463; Fax: (207) 287-8601

TTY: 1-800-606-0215

May 5, 2010

Ranking Member Grassley
Senate Committee on Finance

RE: Director Letter of April 21, 2010

Dear Senator Grassley,

The State of Maine is aware of and vigilant about the potential of fraud, waste and abuse in Medicaid. We share the sense of responsibility to ensure taxpayer dollars are appropriately spent. Because of this, Maine has implemented programs that work to manage fraud, waste and abuse.

For example, this past year we have implemented a 15 day initial prescription limit that allows the prescriber and the patient to test the medication rather than potentially wasting a full 30 days. The member is able to get the additional 15 days if the drug is working and there are no side effects. This program covers products such as long acting narcotics, stimulants and antipsychotic medications.

Maine has also implemented an opiate monitoring program and an antipsychotic prior authorization program. Both are designed to educate providers on alternate plans of care and monitor members utilization of prescription drugs. In addition to the antipsychotic prior authorization, Maine will be introducing antipsychotic medications into our extensive academic detailing program.

For two years, Maine has been collecting and properly disposing of unwanted medications directly from patients and consumers. Through a partnership with the U.S. Postal Service the systematic collection of unwanted medications by our direct mail-back program allows us to accurately identify and characterize what specific medications are prescribed to, purchased by, and returned by patients and consumers because of nonuse or expiration of the medications.

The complete destruction of all returned medications is a controlled, witnessed incineration approved by the U.S. Environmental Protection Agency (EPA) and U.S. Drug Enforcement Agency. Analysis of the raw data collected in Maine through this state-wide program is performed by the Community Medical Foundation for Patient Safety (CMFPS), 6300 West Loop South, Suite 288, Bellaire, TX 77401. In response to your request we pulled the data below:

Sum of Quantity Returned	ABILIFY	GEODON	RISPERDAL	ZYPREXA	OXYCONTIN	SEROQUEL	XANAX	Grand Total
Grand Total	146	502	1781	434	989	899	211	4962

We have expanded on the requested information to include the generic prescriptions and the actual paid amount. Please feel free to contact this office with other questions.

Sincerely,

Anthony Marple
Director, Office of MaineCare Services

CC: Brenda Harvey, Commissioner
Ron Welch, Director, AMHI DHHS

ME Medicaid
Top 10 Prescribers for Selected Mental Health Drugs
CY 2008 and 2009

ABILIFY **2008**

Provider Identifier	Total Prescriptions	Brand Prescriptions	Generic Prescriptions	Total Unique Members	Billed Amount	Paid Amount
BD7349233	568	568	0	145	\$312,023.27	\$203,435.40
BA1742887	440	440	0	83	\$227,680.00	\$164,443.43
BA8340096	398	398	0	69	\$122,774.67	\$94,831.26
MH0843234	365	365	0	109	\$121,436.55	\$94,218.03
AF6911970	308	308	0	51	\$171,213.20	\$127,163.74
MG0908941	307	307	0	60	\$105,588.90	\$77,724.36
AM1090896	302	302	0	98	\$113,261.82	\$57,568.18
BM6519916	277	277	0	50	\$127,502.60	\$101,996.48
MB1452995	273	273	0	74	\$93,690.95	\$28,426.69
MZ1082370	251	251	0	56	\$80,509.04	\$62,417.51

GEODON **2008**

Provider Identifier	Total Prescriptions	Brand Prescriptions	Generic Prescriptions	Total Unique Members	Billed Amount	Paid Amount
BA1742887	309	309	0	48	\$86,276.90	\$54,222.19
BC4313437	301	301	0	46	\$73,668.90	\$46,156.23
MB1452995	232	232	0	43	\$67,484.87	\$38,087.79
AM1090896	226	226	0	49	\$49,985.89	\$15,431.40
MH0843234	215	215	0	51	\$55,859.74	\$40,622.94
AB8186151	204	204	0	33	\$52,435.31	\$33,371.84
MP1221011	167	167	0	23	\$54,775.93	\$39,389.66
MG0514340	164	164	0	30	\$47,193.17	\$27,543.07
MK0407278	158	158	0	33	\$39,465.66	\$27,697.56
AJ1990541	150	150	0	26	\$21,665.17	\$15,444.11

OXYCONTIN **2008**

Provider Identifier	Total Prescriptions	Brand Prescriptions	Generic Prescriptions	Total Unique Members	Billed Amount	Paid Amount
AM1090896	2,489	117	2,372	1,619	\$81,356.96	\$33,178.73
AH1642138	1,066	293	773	152	\$185,799.66	\$79,886.81
MS1585706	696	133	563	151	\$45,205.85	\$17,768.87
MP1454545	677	197	480	150	\$49,958.14	\$20,235.92
BR4300783	641	29	612	57	\$58,277.19	\$20,931.16
BK0161632	629	36	593	55	\$23,409.91	\$11,212.69
MC1545308	620	75	545	139	\$64,279.15	\$28,769.01
ML0517966	569	4	565	54	\$67,153.85	\$20,990.34
AH4926638	547	23	524	40	\$52,514.67	\$18,850.07
MD0026042	542	45	497	72	\$60,491.09	\$30,588.13

RISPERDAL**2008**

Provider Identifier	Total Prescriptions	Brand Prescriptions	Generic Prescriptions	Total Unique Members	Billed Amount	Paid Amount
BD7349233	739	713	26	179	\$149,152.85	\$116,450.74
AM1090896	696	569	127	213	\$130,913.02	\$69,577.07
BT8279386	534	525	9	52	\$97,400.00	\$70,580.59
MG0908941	518	444	74	104	\$88,389.63	\$70,337.15
BH7234711	483	446	37	74	\$82,527.10	\$54,593.86
BA1742887	448	415	33	72	\$108,704.92	\$82,374.34
AJ1990541	434	395	39	71	\$49,013.06	\$40,952.95
MH0843234	388	322	66	120	\$45,480.74	\$36,171.07
MC1044178	362	346	16	65	\$64,010.55	\$48,626.41
AF6911970	356	338	18	69	\$87,918.41	\$65,675.87

ROXICODONE**2008**

Provider Identifier	Total Prescriptions	Brand Prescriptions	Generic Prescriptions	Total Unique Members	Billed Amount	Paid Amount
AM1090896	2,373	1	2,372	1,578	\$54,471.03	\$23,709.11
AH1642138	773	0	773	104	\$89,195.63	\$32,982.03
BR4300783	612	0	612	52	\$49,984.46	\$17,825.23
BK0161632	593	0	593	50	\$17,587.95	\$6,354.14
MS1585706	567	4	563	119	\$32,059.13	\$12,280.90
ML0517966	565	0	565	53	\$67,131.45	\$20,979.14
MC1545308	545	0	545	119	\$36,403.89	\$14,022.30
AH4926638	524	0	524	36	\$43,779.52	\$18,779.26
MD0026042	497	0	497	67	\$41,542.61	\$15,431.09
MP1454545	480	0	480	115	\$27,574.66	\$9,138.85

SEROQUEL**2008**

Provider Identifier	Total Prescriptions	Brand Prescriptions	Generic Prescriptions	Total Unique Members	Billed Amount	Paid Amount
AM1090896	649	649	0	168	\$167,177.95	\$101,693.33
BC4313437	499	499	0	87	\$89,298.79	\$55,160.74
MB1452995	467	467	0	106	\$97,118.46	\$49,272.48
MG0908941	407	407	0	55	\$91,149.85	\$71,643.69
AM2060337	394	394	0	59	\$118,372.67	\$85,885.19
MH0843234	380	380	0	95	\$68,190.25	\$48,615.99
BA1742887	376	376	0	56	\$140,298.33	\$110,998.71
MG0328585	373	373	0	48	\$77,733.53	\$54,807.09
BD7349233	372	372	0	77	\$119,901.88	\$88,601.55
MO1204015	350	350	0	46	\$99,602.25	\$69,020.61

XANAX 2008

Provider Identifier	Total Prescriptions	Brand Prescriptions	Generic Prescriptions	Total Unique Members	Billed Amount	Paid Amount
MH0843234	514	22	492	89	\$18,611.98	\$5,928.31
BT0263323	502	0	502	61	\$26,213.32	\$2,920.54
AG2646264	430	0	430	75	\$13,504.58	\$2,926.87
AM1090896	401	2	399	139	\$7,853.56	\$1,670.32
BC1924174	379	0	379	45	\$9,223.73	\$2,110.26
BB9459771	363	0	363	59	\$15,114.53	\$1,707.23
BR5893032	355	0	355	43	\$9,238.20	\$1,686.71
BB5229213	346	0	346	50	\$12,119.50	\$1,750.13
BS5323756	342	0	342	55	\$10,548.62	\$2,187.62
MB1676519	338	108	230	49	\$29,421.14	\$20,857.68

ZYPREXA 2008

Provider Identifier	Total Prescriptions	Brand Prescriptions	Generic Prescriptions	Total Unique Members	Billed Amount	Paid Amount
AM1090896	255	255	0	74	\$98,377.63	\$35,966.22
MB1452995	252	252	0	43	\$69,898.27	\$28,142.97
MG0328585	214	214	0	28	\$38,671.38	\$18,510.60
MJ1056995	197	197	0	23	\$59,710.85	\$31,990.07
AF1011028	194	194	0	31	\$80,300.58	\$57,228.52
AC8784654	191	191	0	41	\$43,445.13	\$31,526.45
AJ1990541	168	168	0	23	\$30,499.66	\$25,954.90
MH0843234	166	166	0	38	\$41,070.45	\$25,402.68
MH1416812	163	163	0	24	\$27,181.88	\$18,007.58
BA8340096	160	160	0	19	\$51,462.47	\$32,680.70

ABILIFY 2009

Provider Identifier	Total Prescriptions	Brand Prescriptions	Generic Prescriptions	Total Unique Members	Billed Amount	Paid Amount
BD7349233	862	862	0	189	\$453,141.93	\$319,066.34
AF6911970	661	661	0	118	\$277,350.34	\$187,254.13
MP1509833	529	529	0	130	\$127,963.88	\$95,952.29
BA1742887	488	488	0	66	\$243,263.55	\$171,093.21
MT1733814	485	485	0	107	\$171,420.97	\$130,248.91
MH0843234	476	476	0	110	\$140,301.58	\$103,552.59
BA8340096	474	474	0	79	\$117,488.11	\$81,824.15
BZ7300510	413	413	0	109	\$130,177.48	\$89,834.25
AM1090896	382	382	0	105	\$160,353.11	\$85,861.82
MG0908941	374	374	0	93	\$130,261.90	\$104,074.86

GEODON 2009

Provider Identifier	Total Prescriptions	Brand Prescriptions	Generic Prescriptions	Total Unique Members	Billed Amount	Paid Amount
BA1742887	238	238	0	27	\$77,296.49	\$57,734.99
MH0843234	227	227	0	32	\$61,593.88	\$48,538.57
AR4338782	215	215	0	38	\$48,394.60	\$38,819.58
MG0514340	214	214	0	35	\$76,924.40	\$42,262.02
AM1090896	207	207	0	42	\$52,712.03	\$26,484.44
AB8186151	205	205	0	32	\$54,670.69	\$34,834.11
BJ8178104	203	203	0	29	\$58,994.56	\$43,108.02
BA8340096	201	201	0	21	\$49,316.09	\$36,703.07
AS2609381	193	193	0	21	\$32,146.13	\$13,157.11
BC4313437	183	183	0	34	\$50,723.14	\$36,286.00

OXYCONTIN 2009

Provider Identifier	Total Prescriptions	Brand Prescriptions	Generic Prescriptions	Total Unique Members	Billed Amount	Paid Amount
AM1090896	1,867	146	1,721	1,226	\$91,387.79	\$45,820.95
MP1454545	982	337	645	207	\$94,901.97	\$37,146.74
AH1642138	760	354	406	160	\$163,217.21	\$69,886.33
MP1766611	634	29	605	67	\$69,930.21	\$23,826.29
MC1545308	589	96	493	158	\$67,088.13	\$32,833.10
BR4300783	556	16	540	52	\$51,583.08	\$12,915.79
BL8499988	527	47	480	86	\$70,925.39	\$25,054.64
AH2223268	504	171	333	175	\$63,521.78	\$27,730.59
MS1585706	479	133	346	167	\$41,529.54	\$17,923.86
BK0161632	460	34	426	49	\$22,743.92	\$10,213.65

RISPERDAL 2009

Provider Identifier	Total Prescriptions	Brand Prescriptions	Generic Prescriptions	Total Unique Members	Billed Amount	Paid Amount
BD7349233	889	158	731	255	\$151,885.14	\$57,288.33
AM1090896	659	41	618	180	\$108,218.71	\$18,647.41
MG0908941	568	59	509	115	\$75,480.28	\$19,520.08
BH7234711	503	70	433	82	\$75,141.26	\$23,783.19
BA1742887	482	109	373	92	\$98,493.31	\$38,388.98
MH0843234	459	49	410	112	\$49,171.02	\$14,883.58
FM0339590	443	27	416	58	\$55,419.43	\$12,913.76
BT8279386	419	37	382	56	\$65,050.69	\$16,052.57
MB1311492	415	31	384	64	\$69,362.67	\$15,038.29
ML1342978	401	39	362	90	\$80,507.61	\$19,279.33

ROXICODONE 2009

Provider Identifier	Total Prescriptions	Brand Prescriptions	Generic Prescriptions	Total Unique Members	Billed Amount	Paid Amount
AM1090896	1,723	2	1,721	1,188	\$33,567.86	\$10,055.59
MP1454545	649	4	645	153	\$42,824.39	\$10,405.42
MP1766611	607	2	605	59	\$56,043.65	\$16,815.96
BR4300783	540	0	540	48	\$45,052.49	\$12,877.59
MC1545308	493	0	493	137	\$28,417.89	\$7,245.41
BL8499988	480	0	480	75	\$54,584.45	\$15,778.54
BK0161632	426	0	426	45	\$17,637.30	\$5,941.62
AH1642138	406	0	406	95	\$35,797.25	\$9,626.80
MD0026042	371	0	371	48	\$38,727.75	\$12,323.73
BP7351721	349	1	348	45	\$14,990.56	\$5,404.05

SEROQUEL 2009

Provider Identifier	Total Prescriptions	Brand Prescriptions	Generic Prescriptions	Total Unique Members	Billed Amount	Paid Amount
ML1342978	715	715	0	88	\$144,561.55	\$89,129.26
AM1090896	592	592	0	143	\$188,215.09	\$108,311.15
MH0843234	556	556	0	107	\$109,841.37	\$71,755.07
MG0908941	497	497	0	81	\$120,171.66	\$96,602.55
BD7349233	488	488	0	105	\$139,188.66	\$108,863.74
BA1742887	420	420	0	53	\$179,268.57	\$146,584.86
MO1204015	416	416	0	57	\$95,100.59	\$62,579.39
MB1676519	372	372	0	67	\$82,800.72	\$60,575.27
AM2060337	369	369	0	56	\$122,460.21	\$78,775.32
MG0514340	354	354	0	48	\$111,072.33	\$71,230.95

XANAX 2009

Provider Identifier	Total Prescriptions	Brand Prescriptions	Generic Prescriptions	Total Unique Members	Billed Amount	Paid Amount
MH0843234	735	55	680	112	\$35,875.92	\$12,323.27
FD0010671	460	0	460	51	\$8,406.77	\$1,472.05
MB1676519	429	74	355	67	\$32,423.65	\$17,066.98
MO1204015	426	23	403	40	\$10,710.56	\$3,626.64
AG2109709	399	0	399	66	\$13,132.35	\$2,062.61
AG2646264	364	0	364	60	\$13,007.26	\$2,301.16
BG3143473	364	13	351	49	\$15,316.28	\$5,453.07
BC1924174	349	0	349	53	\$9,384.44	\$1,844.54
BB5229213	348	0	348	48	\$12,280.06	\$1,678.77
MD0026042	345	0	345	52	\$15,617.60	\$2,324.08

Provider Identifier	Total Prescriptions	Brand Prescriptions	Generic Prescriptions	Total Unique Members	Billed Amount	Paid Amount
AM1090896	260	260	0	72	\$118,376.93	\$60,490.27
ML1342978	249	249	0	45	\$127,562.04	\$43,259.63
MH0843234	216	216	0	42	\$59,523.96	\$40,911.01
AF1011028	204	204	0	30	\$127,584.06	\$77,690.66
BA8340096	185	185	0	26	\$57,394.57	\$34,988.10
MG0908941	185	185	0	37	\$67,305.91	\$45,896.24
MG0328585	185	185	0	25	\$44,410.26	\$18,954.43
AC8784654	182	182	0	36	\$53,695.15	\$34,111.41
AJ1990541	176	176	0	18	\$50,680.28	\$32,723.32
AH8175386	162	162	0	18	\$95,702.62	\$51,348.47

PATRICK J. LEAHY, VERMONT, CHAIRMAN

HERB KOHL, WISCONSIN
DIANNE FEINSTEIN, CALIFORNIA
CHARLES E. SCHUMER, NEW YORK
RICHARD J. DURBIN, ILLINOIS
SHELDON WHITEHOUSE, RHODE ISLAND
AMY KLOBUCHAR, MINNESOTA
AL FRANKEN, MINNESOTA
CHRISTOPHER A. COONS, DELAWARE
RICHARD BLUMENTHAL, CONNECTICUT

CHARLES E. GRASSLEY, IOWA
ORRIN G. HATCH, UTAH
JON KYL, ARIZONA
JEFF SESSIONS, ALABAMA
LINDSEY O. GRAHAM, SOUTH CAROLINA
JOHN CORNYN, TEXAS
MICHAEL S. LEE, UTAH
TOM COBURN, OKLAHOMA

United States Senate

COMMITTEE ON THE JUDICIARY

WASHINGTON, DC 20510-6275

BRUCE A. COHEN, *Chief Counsel and Staff Director*
KOLAN L. DAVIS, *Republican Chief Counsel and Staff Director*

January 23, 2012

VIA ELECTRONIC TRANSMISSION

Stefanie Nadeau
Director, Office of MaineCare Services
211 State Street
Augusta, Maine 04333-0011

Dear Director Nadeau,

On May 5, 2010, your office provided my staff with data regarding the top ten prescribers of several pain management and mental health drugs in your state. These types of drugs have addictive properties, and the potential for fraud and abuse by prescribers and patients is extremely high. Mental health drugs continue to be prescribed at astounding rates and pain management clinics are turning into a hotbed for black market painkillers. When these drugs are prescribed to Medicaid patients, it is the American people who pay the price for over-prescription, abuse, and fraud.

After an extensive review of prescribing habits of the serial prescribers of pain and mental health drugs in your state, I have concerns about the oversight and enforcement of Medicaid abuse in your state. While I am sensitive to concerns about the potential for misinterpretation of the data you provided, the numbers themselves are quite shocking.

For example, the top prescriber of OxyContin wrote 1867 prescriptions in 2009, nearly double the number of prescriptions than the second top prescriber. This same provider also wrote 1723 prescriptions for Roxicodone, nearly three times the number two top prescriber. This outlier is consistent with several of the antipsychotic drugs—

with the top prescribers writing double or triple the number of prescriptions as the other prescribers on the list.

It is my intention to ensure that each of the states is adequately monitoring, investigating, and stopping fraud and over-prescription of these types of drugs. Therefore, please provide answers to the following questions:


1. What action, if any, has your agency taken with respect to the prescribers identified to the Committee?
2. If there has been no action taken with respect to these prescribers, please explain why not.
3. Please identify which of the providers identified to the Committee remain eligible to bill the Medicaid Program.
4. Please provide the 2010 and 2011 numbers for the top prescribers of these same drugs.
5. Has each of these prescribers been cross-checked for complaints or misconduct with the state medical board or the National Practitioner Data Bank? If not, do you plan to do so?
6. Have any of the prescribers identified to this Committee been referred to your state medical board?
7. Is there any system set up in your state to identify and monitor excessive prescription writing? If not, why not?
8. Have you received any training or guidance from the Centers for Medicare and Medicaid Studies to help identify potential issues with prescription drugs?
9. Does your state maintain a database of all prescribed controlled-substances? If so, what entities have access to it?
10. Does your state have any point-of-sale restrictions related to maximum units, prior authorization, therapeutic duplication, or early refill? If not, why not?
11. Were any of these top ten prescribers identified in the federal-mandated Drug Utilization Review or CMS-base retrospective reviews?
12. Does your state have any programs in place to educate providers about the prescription of antipsychotics to children and adolescents?

Thank you in advance for your cooperation and attention in this matter. When responding to this letter, please number your answers in accordance with my questions. I would appreciate a response by February 13, 2012. If you have any questions, please do not hesitate to contact Erika Smith of my staff at (202) 224-5225.

Sincerely,

A handwritten signature in blue ink that reads "Chuck Grassley". The signature is written in a cursive, flowing style.

Charles E. Grassley
Ranking Member
Committee on the Judiciary



Department of Health and Human Services
MaineCare Services
11 State House Station
Augusta, Maine 04333-0011
Tel. (207) 287-2674
Fax (207) 287-2675; TTY (800) 423-4331

February 17, 2012

Ranking Member Grassley
Senate Committee on Finance

RE: Director Letter of January 23, 2012

Dear Senator Grassley,

The Maine Department of Health and Human Services (DHHS) is aware of, and vigilant, about the potential of fraud, waste and abuse in Medicaid. We share the sense of responsibility to ensure taxpayer dollars are appropriately spent. Therefore, Maine has implemented programs that work to manage fraud, waste and abuse. For example, we have the 15 day limit, an opiate monitoring program, and the antipsychotic prior authorization program. In addition, the Legislature has recently adopted more strict limits on prescribing opiates.

Maine will be introducing antipsychotic medications into our extensive Academic Detailing program. Our detailers plan on providing educational seminars this spring. Currently, the Maine Medical Association also provides an Academic Detailing program on prescribing narcotics.

Please note that the top prescriber on the first list is a hospital, where emergency room staff and all other providers are allowed to use the same master ID. This is why the number is so high. The second highest prescribers on the first and on the second list are both pain managers, so their numbers would be higher for narcotics.

Please see the answers to your other questions below.

- 1. What action, if any, has your agency taken with respect to the prescribers identified to the Committee?**

Please see examples above.

- 2. If there has been no action taken with respect to these prescribers, please explain why not.**

As described above, we have programs in place to address these issues.

- 3. Please identify which of the providers identified to the Committee remain eligible to bill the Medicaid Program.**

All providers identified continue to be eligible to bill Medicaid and receive reimbursement.

- 4. Please provide the 2010 and 2011 numbers for the top prescribers of these same drugs.**

Please see the attachment accompanying this letter.

- 5. Has each of these prescribers been cross-checked for complaints or misconduct with the state medical board or the National Practitioner Data Bank? If not, do you plan to do so?**

No, and we do not currently have plans to do so.

- 6. Have any of the prescribers identified to this Committee been referred to your state medical board?**

No.

- 7. Is there any system set up in your state to identify and monitor excessive prescription writing? If not, why not?**

Yes, we have the intensive benefit program and the prescription monitoring program.

- 8. Have you received any training or guidance from the Centers for Medicare and Medicaid Studies to help identify potential issues with prescription drugs?**

No.

- 9. Does your state maintain a database of all prescribed controlled-substances? If so, what entities have access to it?**

There is the prescription monitoring program that is available to all providers and pharmacies, as well as the program integrity unit and our Pharmacy Benefits Manager.

- 10. Does your state have any point-of-sale restrictions related to maximum units, prior authorization, therapeutic duplication, or early refill? If not, why not?**

Yes.

- 11. Were any of these top ten prescribers identified in the federal-mandated Drug Utilization Review or CMS-base retrospective reviews?**

We have not reviewed these providers in the DUR.

- 12. Does your state have any programs in place to educate providers about the prescription of antipsychotics to children and adolescents?**

Yes, the Department is currently working on an Academic Detailing program for this topic that will be released this spring.

Please feel free to contact Jennifer Palow in the Pharmacy program if you have additional questions. You may reach her by phone 207-287-2705 or email jennifer.palow@maine.gov.

Sincerely,



Stefanie Nadeau
Director, Office of MaineCare Services

CC: Mary Mayhew, Commissioner, Department of Health and Human Services
Kevin Flanigan, Medical Director, Office of MaineCare Services

ME Medicaid
Top 10 Prescribers for Selected Mental Health Drugs
CY 2010 and 2011

ABILIFY		2010				
Provider Identifier	Total Prescriptions	Brand Prescriptions	Generic Prescription	Total Unique Members	Billed Amount	Paid Amount
AF6911970	716	716	0	133	\$300,178.63	\$227,077.05
MG1509136	605	605	0	189	\$172,447.09	\$116,221.30
MT1733814	541	541	0	103	\$174,735.02	\$134,664.46
MG0908941	517	517	0	127	\$135,431.24	\$101,210.72
BM9679905	502	502	0	111	\$119,698.63	\$80,498.23
BA8340096	491	491	0	73	\$133,461.61	\$97,038.22
MO1693438	467	467	0	89	\$158,963.12	\$105,636.75
BM9904954	455	455	0	59	\$135,365.21	\$101,496.03
MP1509833	419	419	0	94	\$93,620.24	\$71,858.18
AM1090896	416	416	0	110	\$172,591.03	\$109,378.50

GEODON		2010				
Provider Identifier	Total Prescriptions	Brand Prescriptions	Generic Prescription	Total Unique Members	Billed Amount	Paid Amount
MG1509136	275	275	0	63	\$73,065.78	\$49,667.43
AR4338782	252	252	0	39	\$69,311.07	\$55,324.11
MG0514340	215	215	0	28	\$75,253.92	\$30,423.83
BJ8178104	204	204	0	32	\$64,058.08	\$36,296.06
MH0843234	186	186	0	30	\$62,463.04	\$50,632.81
MO1204015	182	182	0	26	\$38,891.63	\$30,589.80
AM1090896	177	177	0	42	\$53,829.93	\$20,876.58
MB1916622	168	168	0	21	\$45,312.85	\$36,022.24
BA8340096	154	154	0	15	\$38,242.90	\$26,670.66
MP1521803	148	148	0	26	\$43,769.64	\$35,097.46

OXYCONTIN		2010				
Provider Identifier	Total Prescriptions	Brand Prescriptions	Generic Prescription	Total Unique Members	Billed Amount	Paid Amount
AM1090896	2,972	135	2,837	2,026	\$100,366.11	\$37,775.69
MP1454545	1,242	315	927	308	\$104,687.76	\$33,843.24
AH2223268	1,197	303	894	342	\$116,624.38	\$41,209.90
BL8499988	1,065	106	959	118	\$131,513.29	\$34,910.29
BR4300783	885	59	826	66	\$98,605.53	\$26,867.63
MK0838409	820	179	641	251	\$60,606.96	\$23,300.82
MW1024164	768	316	452	139	\$150,864.45	\$63,326.46
MC1545308	751	129	622	207	\$60,095.58	\$21,174.80
MS1585706	677	183	494	240	\$56,235.10	\$19,716.46
MP1766611	656	41	615	68	\$76,225.75	\$16,689.68

RISPERDAL**2010**

Provider Identifier	Total Prescriptions	Brand Prescriptions	Generic Prescription	Total Unique Members	Billed Amount	Paid Amount
MG0908941	728	26	702	119	\$62,344.23	\$9,295.28
BH7234711	661	15	646	67	\$82,076.95	\$12,258.34
FM0339590	660	0	660	59	\$77,339.75	\$9,106.61
BM6453194	599	23	576	137	\$85,180.19	\$16,165.60
AM1090896	556	10	546	143	\$83,450.50	\$6,562.14
AK3164768	479	14	465	145	\$65,857.10	\$13,067.14
MG1509136	469	5	464	106	\$39,149.87	\$4,449.10
BM9886803	464	11	453	54	\$65,082.60	\$6,642.57
MB1916622	455	0	455	79	\$36,255.58	\$2,988.31
BM2328462	437	6	431	67	\$57,294.38	\$3,660.36

ROXICODONE**2010**

Provider Identifier	Total Prescriptions	Brand Prescriptions	Generic Prescription	Total Unique Members	Billed Amount	Paid Amount
AM1090896	2,838	1	2,837	1,989	\$52,980.99	\$13,214.29
BL8499988	959	0	959	101	\$102,299.67	\$27,315.36
MP1454545	932	5	927	251	\$53,940.71	\$12,361.53
AH2223268	894	0	894	272	\$53,501.60	\$12,807.46
BR4300783	826	0	826	62	\$69,457.26	\$15,149.78
MK0838409	641	0	641	192	\$23,604.43	\$6,230.40
MW0388769	636	0	636	70	\$57,887.94	\$13,693.96
MC1545308	622	0	622	174	\$28,172.76	\$6,684.65
MP1766611	615	0	615	60	\$52,994.82	\$13,414.06
AM9102435	532	0	532	70	\$30,781.25	\$7,845.37

SEROQUEL**2010**

Provider Identifier	Total Prescriptions	Brand Prescriptions	Generic Prescription	Total Unique Members	Billed Amount	Paid Amount
MG0908941	575	575	0	108	\$141,496.68	\$113,972.38
MG1509136	575	575	0	132	\$129,811.70	\$88,072.51
MH0843234	525	525	0	102	\$132,743.20	\$81,936.34
BM9679905	466	466	0	88	\$112,462.97	\$83,581.02
MG0328585	445	445	0	60	\$139,108.85	\$100,056.32
AM1090896	423	423	0	126	\$171,786.86	\$104,617.64
MB1311492	422	422	0	64	\$74,700.27	\$60,260.96
MO1204015	419	419	0	61	\$99,538.89	\$59,383.40
BM2328462	415	415	0	78	\$82,874.69	\$44,200.58
MT1733814	402	402	0	58	\$102,714.87	\$63,455.93

XANAX	2010
--------------	-------------

Provider Identifier	Total Prescriptions	Brand Prescriptions	Generic Prescription	Total Unique Members	Billed Amount	Paid Amount
MH0843234	1,112	0	1,112	146	\$55,587.26	\$11,379.04
MO1204015	617	12	605	48	\$14,063.29	\$3,408.49
MB1676519	541	22	519	88	\$34,318.85	\$10,984.20
FD0010671	458	0	458	63	\$9,600.43	\$1,699.65
MM1252434	456	0	456	48	\$22,480.30	\$3,054.39
AG2646264	434	0	434	69	\$16,730.12	\$2,175.50
MM1677321	431	1	430	90	\$24,232.94	\$5,632.95
AM1090896	424	0	424	110	\$12,261.09	\$1,947.76
MT1733814	421	1	420	66	\$26,243.92	\$3,487.31
MD0026042	421	0	421	51	\$18,782.30	\$2,345.85

ZYPREXA	2010
----------------	-------------

Provider Identifier	Total Prescriptions	Brand Prescriptions	Generic Prescription	Total Unique Members	Billed Amount	Paid Amount
MG1509136	257	257	0	66	\$97,340.54	\$72,519.12
MG0908941	233	233	0	49	\$102,150.76	\$77,210.36
MG0328585	229	229	0	30	\$57,495.18	\$31,996.36
MS1116347	210	210	0	33	\$92,398.27	\$44,306.31
AF1011028	188	188	0	30	\$119,719.22	\$84,527.07
AC8784654	185	185	0	40	\$77,111.92	\$52,877.06
MG0514340	182	182	0	22	\$109,421.62	\$81,819.79
MH0843234	180	180	0	34	\$50,086.23	\$41,644.82
AH8175386	180	180	0	22	\$96,380.21	\$42,657.03
AM1090896	178	178	0	56	\$73,702.23	\$42,972.95

ABILIFY	2011
----------------	-------------

Provider Identifier	Total Prescriptions	Brand Prescriptions	Generic Prescription	Total Unique Members	Billed Amount	Paid Amount
MG1509136	720	720	0	198	\$222,577.31	\$157,737.51
MG0908941	695	695	0	124	\$215,480.35	\$162,074.14
AF6911970	659	659	0	124	\$302,370.99	\$242,088.35
MT1733814	486	486	0	96	\$195,760.10	\$141,572.78
BM6453194	467	467	0	101	\$273,300.70	\$206,171.70
MO1204015	428	428	0	86	\$109,489.68	\$82,920.71
BA8340096	410	410	0	57	\$133,912.03	\$93,494.05
MO1693438	384	384	0	76	\$142,278.47	\$103,121.80
AM1090896	377	377	0	98	\$180,409.48	\$105,587.10
BM2328462	313	313	0	78	\$93,062.66	\$49,362.30
MG0514340	313	313	0	54	\$152,019.59	\$98,770.72

GEODON	2011
---------------	-------------

Provider Identifier	Total Prescriptions	Brand Prescriptions	Generic Prescription	Total Unique Members	Billed Amount	Paid Amount
MG1509136	415	415	0	81	\$123,686.30	\$84,934.99
BJ8178104	269	269	0	30	\$103,395.34	\$48,086.02
MG0908941	245	245	0	23	\$85,588.04	\$55,740.61
MG0514340	220	220	0	31	\$80,102.35	\$22,785.34
MD2171762	211	211	0	32	\$79,222.46	\$49,065.27
AR4338782	196	196	0	33	\$52,651.83	\$44,013.92
MC1044178	189	189	0	20	\$70,162.31	\$33,433.91
MB1916622	178	178	0	16	\$43,410.45	\$36,000.90
AM1090896	171	171	0	30	\$46,934.08	\$20,577.92
MO1204015	158	158	0	26	\$42,610.65	\$31,662.22

OXYCONTIN	2011
------------------	-------------

Provider Identifier	Total Prescriptions	Brand Prescriptions	Generic Prescription	Total Unique Members	Billed Amount	Paid Amount
AM1090896	2,829	85	2,744	1,937	\$76,421.21	\$21,618.88
AH2223268	1,732	363	1,369	404	\$176,342.45	\$58,262.54
MW2096837	949	56	893	145	\$166,125.66	\$37,510.12
BR4300783	945	47	898	59	\$113,756.19	\$43,883.18
FS1168790	937	0	937	315	\$18,913.46	\$5,612.45
BL8499988	918	53	865	101	\$108,256.40	\$22,635.88
MK0838409	735	153	582	208	\$47,357.50	\$17,396.12
BG5793751	699	121	578	166	\$62,464.16	\$28,999.84
MP1454545	669	125	544	230	\$51,279.48	\$12,117.37
AE1097282	639	94	545	176	\$30,558.76	\$10,085.09

RISPERDAL	2011
------------------	-------------

Provider Identifier	Total Prescriptions	Brand Prescriptions	Generic Prescription	Total Unique Members	Billed Amount	Paid Amount
MG0908941	825	40	785	111	\$81,537.30	\$13,243.99
BM6453194	737	43	694	131	\$106,710.73	\$22,229.54
BH7234711	658	13	645	69	\$81,689.84	\$10,565.21
FM0339590	614	0	614	68	\$63,628.40	\$5,604.36
BM9886803	564	10	554	59	\$73,601.28	\$6,023.41
MG1509136	564	0	564	121	\$51,162.42	\$2,669.07
AM1090896	491	15	476	122	\$76,335.22	\$6,673.38
AB1442653	450	0	450	55	\$76,361.49	\$1,648.53
BC7392373	394	1	393	54	\$52,901.91	\$2,019.10
BM2328462	390	9	381	62	\$39,484.34	\$2,093.37

ROXICODONE 2011

Provider Identifier	Total Prescriptions	Brand Prescriptions	Generic Prescription	Total Unique Members	Billed Amount	Paid Amount
AM1090896	2,744	0	2,744	1,908	\$56,801.16	\$14,187.04
AH2223268	1,369	0	1,369	324	\$81,756.18	\$18,365.89
FS1168790	937	0	937	315	\$18,913.46	\$5,612.45
BR4300783	898	0	898	57	\$67,685.36	\$13,165.44
MW2096837	893	0	893	133	\$149,770.20	\$37,161.74
BL8499988	865	0	865	90	\$102,072.95	\$20,607.34
MK0838409	582	0	582	171	\$19,831.42	\$4,284.55
MD0026042	582	0	582	68	\$61,210.09	\$12,410.57
BG5793751	580	2	578	136	\$26,184.73	\$4,979.58
BR5893032	567	0	567	67	\$61,311.52	\$9,422.95

SEROQUEL 2011

Provider Identifier	Total Prescriptions	Brand Prescriptions	Generic Prescription	Total Unique Members	Billed Amount	Paid Amount
MG0908941	679	679	0	115	\$185,721.33	\$140,382.75
MG1509136	675	675	0	153	\$177,889.22	\$129,323.25
MG0328585	489	489	0	56	\$179,960.85	\$123,174.99
MT1733814	448	448	0	61	\$161,706.88	\$108,782.68
MO1204015	415	415	0	76	\$123,295.48	\$70,329.96
MC0909563	391	391	0	59	\$109,661.19	\$75,574.04
MB1311492	374	374	0	48	\$104,495.38	\$84,030.70
AM1090896	366	366	0	97	\$149,573.20	\$80,540.95
BM6453194	357	357	0	67	\$147,533.08	\$108,433.55
BM2328462	345	345	0	63	\$97,411.76	\$36,513.52

XANAX 2011

Provider Identifier	Total Prescriptions	Brand Prescriptions	Generic Prescription	Total Unique Members	Billed Amount	Paid Amount
MT1733814	1,061	1	1,060	134	\$56,528.03	\$6,495.61
FD0010671	747	0	747	81	\$14,168.62	\$1,912.34
MO1204015	688	2	686	65	\$17,427.66	\$2,497.32
MM1724485	644	0	644	89	\$50,874.45	\$6,532.91
MH0843234	584	0	584	79	\$34,283.95	\$5,251.44
AG2646264	494	0	494	74	\$21,142.16	\$1,946.96
MM1677321	446	0	446	54	\$28,312.24	\$5,270.50
BG3143473	444	0	444	55	\$18,980.86	\$2,777.27
AP9566641	435	0	435	51	\$19,163.27	\$2,117.29
AM2060337	377	0	377	38	\$20,057.60	\$1,889.20

Provider Identifier	Total Prescriptions	Brand Prescriptions	Generic Prescription	Total Unique Members	Billed Amount	Paid Amount
MG0908941	358	355	3	66	\$139,784.82	\$101,078.67
MG1509136	300	297	3	72	\$121,156.06	\$88,076.92
MG0328585	250	240	10	39	\$88,606.75	\$52,996.50
MD2171762	213	212	1	41	\$165,706.83	\$109,663.99
AF1011028	199	196	3	39	\$131,587.50	\$107,129.02
AM1090896	199	190	9	52	\$109,937.77	\$73,513.89
AC8784654	197	188	9	42	\$88,415.53	\$51,261.94
AH8175386	172	163	9	21	\$115,481.66	\$54,460.48
MB1311492	165	163	2	20	\$101,816.03	\$70,881.73
BL3130868	149	140	9	25	\$99,868.90	\$40,427.11